BioKeralty Research Institute is part of Keralty group’s research, development and innovation (R&D&I) division. Following the Keralty’s health model principles, BioKeralty drives and coordinates research and development projects in several health areas. The main research areas are: chronic diseases, regenerative medicine, cancer, personalized medicine or digital health, as well as health value, social care and community care.
Thought its participation in several partnerships, R&D&I projects and related calls, Keralty group works in the implementation of attention models, management models and health technologies and tools. In this way, Keralty aims to create competitive advantage that will allow the group share and add value to its patients and health professionals.
In the absence of useful therapies for any type of patients, the NoCanTher project seeks to demonstrate the applicability of nanoparticles in the treatment of pancreatic cancer. Having BioKeralty as sponsor, the clinical study was the last stage of the European NoCanTher…
Next February 3 the final workshop of the European Smart4Fabry project will take place. The objective of this project is to obtain a new GLA nanoformulation to manage Fabry disease making possible to improve the efficacy and tolerance of the current treatments.
For those people interested in the scientific publications and patents developed by the BioKeralty team, this section gathers detailed information and useful references corresponding to its scientific research. Nanomaterials, biomedical applications, in vitro and in vivo antimicrobial activities, nanomedicine, fatty acids, nanofibrous membranes, tissue reparations, etc. constitute some of the research topics included in this section.
Primary care
Cancer
Chronic and neurodegenerative
Infectious diseases
E-health
Genomics and personalized
Regenerative medicine
Nanotechnology
Education
Community
Social
Health value